Abstract
Neuroendocrine cancer. An activating hotspot mutation in PRKACA provides clues for adrenal Cushing syndrome therapeutics.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Nature clinical practice. Endocrinology & metabolism
Paper Title
Journal
Date
